Enveda raises $311 million to turn nature's chemistry into drugs
A biotech that reads molecules out of plants and microbes just raised the largest round of the week — and a 2.5B open model showed up to embarrass models twice its size.
Enveda has raised $311 million in a Series E led by Catalio Capital Management, at a $2 billion valuation that doubles what the company was worth twelve months ago. The Boulder, Colorado company does not design molecules from scratch; it searches for them. Its PRISM platform uses machine learning and metabolomics to identify compounds inside plants and microbes, predict their structure and function, and rank them by drug potential — a pipeline its chemists then turn into candidates. Chief executive Viswa Colluru, who founded the company in 2019 after a stint at Recursion Pharmaceuticals, frames the bet as a correction: "We started Enveda on a different premise: the most reliable source of new medicines is the chemistry that living things have been refining for billions of years, and AI finally lets us read it."
The round brings Enveda's total fundraising to more than $845 million, and the money is going into trials rather than more platform work. The company says it has produced 17 candidates to date with three now in human testing. ENV-294, for atopic dermatitis and asthma, is in Phase 2a; ENV-308, aimed at weight-loss maintenance after GLP-1 drugs, cleared a Phase 1 tolerability readout in August; ENV-6946 for inflammatory bowel disease is headed through mid-stage development. BioSpace reports new trials are expected "in the coming months." ICONIQ, T. Rowe Price, Surveyor Capital, Durable Capital Partners, Lightspeed and Lux Capital joined Catalio, alongside a sovereign wealth fund that BioPharma Dive did not name.
The reason this round matters beyond the number is what it says about where AI drug discovery has settled. The 2023–24 pitch was generation — models inventing novel molecules, a framing that ran into a wall of undruggable designs and long preclinical timelines. Enveda's version inverts it: use AI to find what already works biologically, then let chemists finish the job. It is a slower, less cinematic claim, and it is the one a $2 billion valuation just got attached to. We covered the same shift in July, when Basecamp Research raised $140 million to train AI on the planet's DNA — the bet there was on data, here it is on the search itself.
OpenBMB released MiniCPM5-2B, a 2.5-billion-parameter model that beats 4B-class rivals on coding and agent benchmarks — including Alibaba's Qwen3.5-4B. The headline number going around is a 13-point gap, and it is real on exactly one test: SWE-bench Verified, where MiniCPM5-2B scores 46.4 against Qwen3.5-4B's 33.6. It also leads on LiveCodeBench v6 (69.1 to 56.4) and NoLiMa long-context (68.1 to 43.5). But the 13 points is a cherry-pick from a single benchmark. Across OpenBMB's own 34-benchmark average the gap is 2.8 points, 53.9 to 51.1 — and Qwen3.5-4B actually wins on MMLU-Pro (78.0 to 70.8) and MMLU-Redux (88.7 to 84.7).
Independent evaluators are less impressed than the release table. Artificial Analysis scores MiniCPM5-2B at 12 on its Intelligence Index, with Qwen3.5-4B Reasoning at 13 — the composite index does not reproduce the upset, and most of the benchmark numbers are company-reported. What is not in dispute is the packaging: 2.52 billion parameters total, 131,072-token context, Apache 2.0, and traction that speaks for itself at 564,000 downloads in the last month. For a phone-sized model, that is the whole pitch — capability per gigabyte, not per leaderboard.
What to watch: whether Enveda's Phase 2a readouts land before the next funding cycle, and whether anyone runs MiniCPM5-2B against Qwen3.5-4B on a third-party harness rather than the model card.
If a company's own benchmark table is the only place its model wins, should that count as a release or a claim? Tell us in the comments.
Sources: TechCrunch · BioSpace · BioPharma Dive · Enveda · OpenBMB — MiniCPM5-2B model card · Artificial Analysis · Tech Times · AI Midday — Basecamp Research raises $140 million
